JW Lifescience Corporation (KRX:234080)

Market Cap	196.81B
Revenue (ttm)	248.30B +12.2%
Net Income	47.59B +65.1%
EPS	3,073.31 +65.1%
Shares Out	15.48M
PE Ratio	4.14
Forward PE	n/a
Dividend	500.00 (3.92%)
Ex-Dividend Date	Dec 27, 2024

Volume	122,237
Average Volume	43,213
Open	12,710
Previous Close	12,710
Day's Range	12,360 - 13,100
52-Week Range	10,000 - 15,580
Beta	0.35
RSI	43.95
Earnings Date	Feb 5, 2026

About JW Lifescience

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 297
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 234080

Financial Performance

In 2024, JW Lifescience's revenue was 222.48 billion, an increase of 7.55% compared to the previous year's 206.86 billion. Earnings were 43.99 billion, an increase of 56.29%.